

Raymond T Chung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1238823/publications.pdf>

Version: 2024-02-01

396
papers

25,749
citations

6254

80
h-index

9345

143
g-index

405
all docs

405
docs citations

405
times ranked

27798
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 125-135.e8.	4.4	3
2	A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (<sc>HBV</sc>)â€HIV</sc> coâ€infection with high prevalence of tenofovirâ€based antiretroviral therapy use. <i>HIV Medicine</i> , 2023, 24, 55-74.	2.2	2
3	Implementation of a controlled human infection model for evaluation of HCV vaccine candidates. <i>Hepatology</i> , 2023, 77, 1757-1772.	7.3	5
4	Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 256-268.	4.4	34
5	Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBVâ€HIV Co-infected Adults. <i>Digestive Diseases and Sciences</i> , 2022, 67, 676-688.	2.3	4
6	[18F]MAGL-4-11 positron emission tomography molecular imaging of monoacylglycerol lipase changes in preclinical liver fibrosis models. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 308-315.	12.0	11
7	Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2022, 6, 309-319.	4.3	11
8	Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 599-609.	4.7	12
9	Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2022, 225, 19-29.	4.0	19
10	Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward. <i>American Journal of Kidney Diseases</i> , 2022, 79, 737-745.	1.9	22
11	Pilot Randomized Controlled Trial of an Advance Care Planning Video Decision Tool for Patients With Advanced Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2287-2295.e3.	4.4	9
12	Incidence and prediction of HBsAg seroclearance in a prospective multiâ€ethnic HBeAgâ€negative chronic hepatitis B cohort. <i>Hepatology</i> , 2022, 75, 709-723.	7.3	13
13	Reply. <i>Hepatology</i> , 2022, 75, 761-763.	7.3	0
14	One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-Infected kidneys (MYTHIC) Trial. <i>Kidney International Reports</i> , 2022, 7, 241-250.	0.8	12
15	Reply. <i>Hepatology</i> , 2022, 75, 1055-1056.	7.3	1
16	A New Model to Assess Hepatitis B Virus Covalently Closed Circular DNA: A Window Into a Previously Hidden Space?. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1255-1256.	4.5	2
17	Hepatitis B and Hepatitis C Virus Infection Promote Liver Fibrogenesis through a TGF-Î²1â€Induced OCT4/Nanog Pathway. <i>Journal of Immunology</i> , 2022, 208, 672-684.	0.8	12
18	Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQ1 ²¹ . <i>American Journal of Human Genetics</i> , 2022, 109, 299-310.	6.2	6

#	ARTICLE	IF	CITATIONS
19	Preliminary evaluation of [11C]MAGL-0519 as a promising PET ligand for the diagnosis of Hepatocellular carcinoma. <i>Bioorganic Chemistry</i> , 2022, 120, 105620.	4.1	0
20	Substance Use Disorder Is Associated With Alcohol-Associated Liver Disease in Patients With Alcohol Use Disorder. , 2022, 1, 403-408.		0
21	Reply to Li, Henry, and Nguyen. <i>American Journal of Gastroenterology</i> , 2022, 117, 688-688.	0.4	0
22	Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of <i>PP2R1B</i> . <i>Science Translational Medicine</i> , 2022, 14, eabh3831.	12.4	11
23	Changes in serum hepatitis B surface and e antigen, interferon- γ -inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. <i>Hepatology</i> , 2022, 76, 775-787.	7.3	7
24	Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient. <i>Hepatology Communications</i> , 2022, 6, 2079-2089.	4.3	22
25	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. <i>Gastroenterology</i> , 2022, 162, 1210-1225.	1.3	17
26	Persistent Cholestatic Injury and Secondary Sclerosing Cholangitis in COVID-19 Patients. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 1184-1193.	2.5	11
27	Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature. <i>Hepatology Communications</i> , 2022, 6, 2581-2593.	4.3	12
28	Abstract 255: Peroxidase deficiency recruits pro-healing macrophages into the liver and inhibits NAFLD progression to HCC. <i>Cancer Research</i> , 2022, 82, 255-255.	0.9	0
29	Burdensome Transitions of Care for Patients with End-Stage Liver Disease and Their Caregivers. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2942-2955.	2.3	19
30	Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2021, 73, e3275-e3285.	5.8	15
31	Liver Biochemistries in Hospitalized Patients With COVID-19. <i>Hepatology</i> , 2021, 73, 890-900.	7.3	157
32	Reply. <i>Hepatology</i> , 2021, 73, 875-876.	7.3	0
33	Mobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning. <i>ACS Nano</i> , 2021, 15, 665-673.	14.6	21
34	Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. <i>Hepatology</i> , 2021, 73, 548-559.	7.3	49
35	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. <i>Hepatology</i> , 2021, 73, 1637-1651.	7.3	11
36	Fatty Acids Activate the Transcriptional Coactivator YAP1 to Promote Liver Fibrosis via p38 Mitogen-Activated Protein Kinase. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 1297-1310.	4.5	28

#	ARTICLE	IF	CITATIONS
37	Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1568-1582.	3.6	21
38	OUP accepted manuscript. <i>Clinical Infectious Diseases</i> , 2021, , .	5.8	0
39	The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence. <i>Hepatology</i> , 2021, 74, 2813-2823.	7.3	4
40	Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2021, 116, 1686-1697.	0.4	20
41	Patient and Caregiver Perspectives on Palliative Care in End-Stage Liver Disease. <i>Journal of Palliative Medicine</i> , 2021, 24, 719-724.	1.1	17
42	Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00359.	2.5	57
43	Growth Hormone Releasing Hormone Reduces Plasma Markers of Immune Activation and Hepatic Immune Pathways in Nonalcoholic Fatty Liver Disease. <i>Journal of the Endocrine Society</i> , 2021, 5, A628-A629.	0.2	0
44	Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease 2019 Severity. <i>Journal of Infectious Diseases</i> , 2021, 224, 777-782.	4.0	26
45	The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. <i>Liver International</i> , 2021, 41, 2341-2357.	3.9	3
46	An exploratory analysis of the competing effects of alcohol use and advanced hepatic fibrosis on serum HDL. <i>Clinical and Experimental Medicine</i> , 2021, , 1.	3.6	1
47	Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans. <i>Nature Immunology</i> , 2021, 22, 1020-1029.	14.5	124
48	Hepatic Encephalopathy is Associated With Slow Speech on Objective Assessment. <i>American Journal of Gastroenterology</i> , 2021, 116, 1950-1953.	0.4	10
49	Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory. <i>Nature Immunology</i> , 2021, 22, 1030-1041.	14.5	63
50	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. <i>Med</i> , 2021, 2, 836-850.e10.	4.4	31
51	American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. <i>Hepatology</i> , 2021, 74, 1049-1064.	7.3	136
52	A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America. <i>Hepatology</i> , 2021, 74, 1174-1189.	7.3	11
53	Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. <i>Hepatology</i> , 2021, 74, 2395-2409.	7.3	36
54	Serum HMGB1 associates with liver disease and predicts readmission and mortality in patients with alcohol use disorder. <i>Alcohol</i> , 2021, 95, 37-43.	1.7	8

#	ARTICLE	IF	CITATIONS
55	Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. <i>Scientific Reports</i> , 2021, 11, 18045.	3.3	36
56	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. <i>Nature Communications</i> , 2021, 12, 5525.	12.8	21
57	Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy. <i>Annals of Hepatology</i> , 2021, 25, 100333.	1.5	18
58	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021, 13, eabe8939.	12.4	17
59	Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease. <i>Kidney International</i> , 2020, 97, 193-201.	5.2	44
60	Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults. <i>Hepatology</i> , 2020, 71, 411-421.	7.3	23
61	High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia. <i>Journal of Infectious Diseases</i> , 2020, 221, 218-222.	4.0	29
62	Computed Tomography Findings as a Novel Predictor of Alcohol-Associated Hepatitis Outcomes. <i>Digestive Diseases and Sciences</i> , 2020, 65, 312-321.	2.3	2
63	New approaches in viraemic organ transplantation and antiviral therapies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 78-79.	17.8	3
64	Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. <i>American Journal of Transplantation</i> , 2020, 20, 1619-1628.	4.7	31
65	Health Care Utilization and End-of-Life Care Outcomes for Patients With Decompensated Cirrhosis Based on Transplant Candidacy. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 590-598.	1.2	37
66	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020, 31, 406-421.e7.	16.2	141
67	Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical Practice. <i>American Journal of Gastroenterology</i> , 2020, 115, 783-785.	0.4	27
68	A MicroRNA Linking Human Positive Selection and Metabolic Disorders. <i>Cell</i> , 2020, 183, 684-701.e14.	28.9	46
69	Shortening treatment with direct-acting antivirals in HCV-positive organ transplantation. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 626-627.	8.1	2
70	Acute Kidney Injury Following Paracentesis Among Inpatients With Cirrhosis. <i>Kidney International Reports</i> , 2020, 5, 1305-1308.	0.8	3
71	Modeling the Hepatology Workforce in the United States: A Predicted Critical Shortage. <i>Hepatology</i> , 2020, 72, 1444-1454.	7.3	26
72	Low Complement C4 Predicts Improvement of Kidney Function After Direct-Acting Antiviral Therapy for Hepatitis C Virus. <i>Hepatology Communications</i> , 2020, 4, 1206-1217.	4.3	2

#	ARTICLE	IF	CITATIONS
73	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. <i>Hepatology</i> , 2020, 72, 1819-1837.	7.3	17
74	Gamma-Glutamyltransferase Elevation Is Frequent in Patients With COVID-19: A Clinical Epidemiologic Study. <i>Hepatology Communications</i> , 2020, 4, 1744-1750.	4.3	23
75	Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2678-2687.	6.1	55
76	Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	71
77	Virus detection using nanoparticles and deep neural network-enabled smartphone system. <i>Science Advances</i> , 2020, 6, .	10.3	39
78	Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?. <i>Journal of Infectious Diseases</i> , 2020, 222, S802-S813.	4.0	14
79	Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 11667-11673.	7.1	50
80	Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis. <i>Blood</i> , 2020, 136, 726-739.	1.4	297
81	Maternal knowledge of the risk of vertical transmission and offspring acquisition of hepatitis B. <i>Annals of Hepatology</i> , 2020, 19, 388-395.	1.5	7
82	Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. <i>New England Journal of Medicine</i> , 2020, 382, 1018-1028.	27.0	208
83	[18F]-Alfatide PET imaging of integrin $\alpha_5\beta_1$ for the non-invasive quantification of liver fibrosis. <i>Journal of Hepatology</i> , 2020, 73, 161-169.	3.7	17
84	Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. <i>Journal of Hepatology</i> , 2020, 73, 62-71.	3.7	60
85	Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation. <i>Kidney International Reports</i> , 2020, 5, 459-467.	0.8	16
86	Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts. <i>Journal of Hepatology</i> , 2020, 72, 1062-1069.	3.7	32
87	Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 972-980.	1.5	10
88	Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. <i>Hepatology</i> , 2020, 72, 287-304.	7.3	408
89	Cognitive Tests and Stool Frequency at Hospital Discharge Do Not Predict Outcomes in Hepatic Encephalopathy. <i>Southern Medical Journal</i> , 2020, 113, 578-584.	0.7	1
90	Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. <i>Hepatology</i> , 2019, 69, 2338-2348.	7.3	37

#	ARTICLE	IF	CITATIONS
91	Serum Angiotensin-converting Enzyme Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis. <i>Hepatology</i> , 2019, 69, 729-741.	7.3	26
92	Patients With Cirrhosis Require More Fecal Microbiota Capsules to Cure Refractory and Recurrent <i>Clostridium difficile</i> Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 791-793.	4.4	18
93	Provider Attitudes toward the Use of Hepatitis C Virus-Positive Organs in Kidney Transplantation. <i>American Journal of Nephrology</i> , 2019, 50, 168-176.	3.1	8
94	Outcomes of Palliative Care Consultations for Hospitalized Patients With Liver Disease. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 766-773.	1.2	19
95	Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 771-780.	8.1	66
96	Drug-Resistant <i>E. coli</i> Bacteremia Transmitted by Fecal Microbiota Transplant. <i>New England Journal of Medicine</i> , 2019, 381, 2043-2050.	27.0	767
97	Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 477-479.e4.	4.5	4
98	Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement. <i>PLoS ONE</i> , 2019, 14, e0217442.	2.5	23
99	Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. <i>PLoS Genetics</i> , 2019, 15, e1008181.	3.5	109
100	Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2592-2599.	4.4	67
101	Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2776-2784.e4.	4.4	108
102	Editorial: mind the gaps – an important first step towards improving hepatic encephalopathy care. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1534-1535.	3.7	0
103	Process of selecting and educating HCV-uninfected kidney waiting list candidates for HCV-infected kidney transplantation. <i>Artificial Organs</i> , 2019, 43, 913-920.	1.9	5
104	Outcomes of in-hospital cardiopulmonary resuscitation for patients with end-stage liver disease. <i>Liver International</i> , 2019, 39, 1256-1262.	3.9	17
105	Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein subfractions: a post-hoc analysis of the PIVENS trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1205-1213.	3.7	24
106	Microrna-130a Downregulates HCV Replication through an atg5-Dependent Autophagy Pathway. <i>Cells</i> , 2019, 8, 338.	4.1	19
107	Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study. <i>Liver Transplantation</i> , 2019, 25, 859-869.	2.4	40
108	Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. <i>Clinical Infectious Diseases</i> , 2019, 69, 514-522.	5.8	20

#	ARTICLE	IF	CITATIONS
109	Direct-acting antiviral treatment for hepatitis C. <i>Lancet</i> , The, 2019, 393, 1392-1394.	13.7	47
110	Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. <i>Annals of Internal Medicine</i> , 2019, 171, 318.	3.9	95
111	Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 351-357.	1.6	6
112	Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring. <i>Liver International</i> , 2019, 39, 740-747.	3.9	26
113	A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6. <i>Hepatology</i> , 2019, 69, 1004-1019.	7.3	45
114	Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago. <i>American Journal of Nephrology</i> , 2019, 49, 32-40.	3.1	21
115	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 746-757.	0.4	33
116	Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 362-372.	2.0	21
117	Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 739-747.e8.	4.4	24
118	Antiviral activity of bone morphogenetic proteins and activins. <i>Nature Microbiology</i> , 2019, 4, 339-351.	13.3	39
119	Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. <i>Methods in Molecular Biology</i> , 2019, 1911, 3-32.	0.9	80
120	No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis. <i>Hepatoma Research</i> , 2019, 2019, .	1.5	14
121	Reply. <i>Hepatology</i> , 2018, 68, 793-793.	7.3	0
122	Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients. <i>Hemodialysis International</i> , 2018, 22, S71-S80.	0.9	11
123	A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study. <i>Liver International</i> , 2018, 38, 1495-1503.	3.9	34
124	MicroRNA 130a Regulates both Hepatitis C Virus and Hepatitis B Virus Replication through a Central Metabolic Pathway. <i>Journal of Virology</i> , 2018, 92, .	3.4	32
125	Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient. <i>Kidney International</i> , 2018, 93, 560-567.	5.2	46
126	Reply. <i>Hepatology</i> , 2018, 67, 1641-1642.	7.3	1

#	ARTICLE	IF	CITATIONS
127	Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 16-25.	4.5	103
128	Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. <i>Hemodialysis International</i> , 2018, 22, S81-S96.	0.9	27
129	Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. <i>Diabetes Care</i> , 2018, 41, 1251-1259.	8.6	21
130	Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. <i>Hepatology</i> , 2018, 68, 1125-1139.	7.3	74
131	Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis. <i>International Journal of Cardiology</i> , 2018, 259, 198-204.	1.7	53
132	Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 115-122.e10.	4.4	21
133	Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. <i>Hepatology</i> , 2018, 67, 837-846.	7.3	61
134	Live cell imaging of cytosolic NADH/NAD ⁺ ratio in hepatocytes and liver slices. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G97-G108.	3.4	20
135	When and how can nephrologists treat hepatitis C virus infection in dialysis patients?. <i>Seminars in Dialysis</i> , 2018, 31, 26-36.	1.3	11
136	Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment. <i>Digestive Diseases and Sciences</i> , 2018, 63, 486-492.	2.3	69
137	Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. <i>Hepatology</i> , 2018, 67, 2085-2095.	7.3	50
138	The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. <i>Hepatology</i> , 2018, 67, 2244-2253.	7.3	137
139	Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. <i>Hepatology</i> , 2018, 67, 1797-1806.	7.3	100
140	Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1683.	7.1	170
141	Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 67, 1477-1492.	5.8	509
142	The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. <i>International Journal of Cardiology</i> , 2018, 270, 245-252.	1.7	51
143	<i>IRGM</i> Gene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2247-2257.	1.9	19
144	Reactivation of a Vaccine Escape Hepatitis B Virus Mutant in a Cambodian Patient During Anti-Hepatitis C Virus Therapy. <i>Frontiers in Medicine</i> , 2018, 5, 97.	2.6	2

#	ARTICLE	IF	CITATIONS
145	Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2112-2119.	3.0	15
146	Opioid Use Disorder, Stigma, and Transplantation: A Call to Action. <i>Annals of Internal Medicine</i> , 2018, 169, 188.	3.9	9
147	Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2018, 218, 1394-1403.	4.0	36
148	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1123-1128.	7.1	133
149	Heat stroke leading to acute liver injury & failure: A case series from the Acute Liver Failure Study Group. <i>Liver International</i> , 2017, 37, 509-513.	3.9	48
150	Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection. <i>Hepatology</i> , 2017, 66, 658-660.	7.3	19
151	Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 147-163.	1.6	10
152	Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	37
153	Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV)-Positive and HCV-Negative Men at Various Lipid Levels: Results From ERCHIVES. <i>Clinical Infectious Diseases</i> , 2017, 65, 557-565.	5.8	27
154	Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 651-672.	2.4	44
155	Reply. <i>Hepatology</i> , 2017, 66, 1005-1006.	7.3	0
156	Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells. <i>Scientific Reports</i> , 2017, 7, 44867.	3.3	22
157	Validation of Shear Wave Elastography Cutoff Values on the Supersonic Aixplorer for Practical Clinical Use in Liver Fibrosis Staging. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 1125-1133.	1.5	19
158	Most ApoL1 Is Secreted by the Liver. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1079-1083.	6.1	44
159	Benefits of Direct-Acting Antivirals for Hepatitis C. <i>Annals of Internal Medicine</i> , 2017, 167, 812.	3.9	13
160	Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8+ T Cells in Chronic versus Acute Infection. <i>Immunity</i> , 2017, 47, 648-663.e8.	14.3	50
161	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1981.	4.4	0
162	IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. <i>Clinical Infectious Diseases</i> , 2017, 65, 1773-1775.	5.8	11

#	ARTICLE	IF	CITATIONS
163	NAM 2017 report: A national plan to eliminate hepatitis B and C in the United States by 2030 and the AASLD's response. <i>Hepatology</i> , 2017, 66, 1020-1022.	7.3	9
164	Comments on cochrane review on direct-acting antivirals for hepatitis C. <i>Hepatology</i> , 2017, 66, 1016-1019.	7.3	3
165	Intermittent hypoxia is a proinflammatory stimulus resulting in IL-6 expression and M1 macrophage polarization. <i>Hepatology Communications</i> , 2017, 1, 326-337.	4.3	29
166	Model for end-stage liver disease Na Score predicts incident major cardiovascular events in patients with nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2017, 1, 429-438.	4.3	9
167	Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus Infection in Organ Transplantation. <i>ACS Infectious Diseases</i> , 2017, 3, 620-623.	3.8	10
168	Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. <i>Scientific Reports</i> , 2017, 7, 15843.	3.3	6
169	Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e101.	2.5	124
170	Bi-directional analysis between fatty liver and cardiovascular disease risk factors. <i>Journal of Hepatology</i> , 2017, 66, 390-397.	3.7	152
171	Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. <i>Hepatology</i> , 2017, 65, 777-788.	7.3	83
172	Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. <i>Hepatology</i> , 2017, 65, 1156-1164.	7.3	76
173	Use of proton pump inhibitors in chronic liver diseases. <i>Clinical Liver Disease</i> , 2017, 10, 148-151.	2.1	11
174	The Incidence of Hepatocellular Carcinoma Is not Increased in Individuals with Chronic Hepatitis C After Treatment with Interferon-free Regimens: an ERCHIVES Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, S41-S41.	0.9	1
175	Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. <i>Clinical Infectious Diseases</i> , 2017, 64, 1035-1042.	5.8	42
176	HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus. <i>Frontiers in Microbiology</i> , 2017, 8, 240.	3.5	38
177	Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy. <i>World Journal of Gastroenterology</i> , 2017, 23, 6868-6876.	3.3	45
178	Direct-Acting Antiviral (DAA) Therapy for Chronic Hepatitis C Virus (HCV) Infection Leads to Regression of Liver Fibrosis, Assessed by Serial Transient Elastography (Fibroscan). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
179	Lipid Levels and the Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV) Infected and Uninfected Persons: Results From ERCHIVES. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
180	Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. <i>Hepatology</i> , 2016, 63, 408-417.	7.3	226

#	ARTICLE	IF	CITATIONS
181	Reply. <i>Hepatology</i> , 2016, 63, 2066-2067.	7.3	0
182	Sofosbuvir-based regimens in clinical practice achieve <sc>SVR</sc> rates closer to clinical trials: results from <sc>ERCHIVES</sc>. <i>Liver International</i> , 2016, 36, 651-658.	3.9	33
183	Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. <i>Hepatology</i> , 2016, 64, 47-57.	7.3	147
184	Impact of <i><sc>EGF</sc></i>, <i><sc>IL</sc>28B</i>, and <i><sc>PNPLA</sc>3</i> polymorphisms on the outcome of allograft hepatitis C: a multicenter study. <i>Clinical Transplantation</i> , 2016, 30, 452-460.	1.6	2
185	Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from <sc>ERCHIVES</sc>. <i>Liver International</i> , 2016, 36, 1275-1283.	3.9	25
186	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016, 30, 879-890.	16.8	172
187	Chronic hepatitis C infection-induced liver fibrogenesis is associated with M2 macrophage activation. <i>Scientific Reports</i> , 2016, 6, 39520.	3.3	53
188	HCV induces transforming growth factor β 1 through activation of endoplasmic reticulum stress and the unfolded protein response. <i>Scientific Reports</i> , 2016, 6, 22487.	3.3	66
189	Racial Disparities in Inhospital Outcomes for Hepatocellular Carcinoma in the United States. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1173-1182.	3.0	15
190	Lupus-Like Immune Complex-Mediated Glomerulonephritis in Patients With Hepatitis C Virus Infection Treated With Oral, Interferon-Free, Direct-Acting Antiviral Therapy. <i>Kidney International Reports</i> , 2016, 1, 135-143.	0.8	26
191	Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. <i>BMC Infectious Diseases</i> , 2016, 16, 393.	2.9	29
192	Siglec-7 as a Novel Biomarker to Predict Mortality in Decompensated Cirrhosis and Acute Kidney Injury. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3609-3620.	2.3	8
193	Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3425-3435.	2.3	14
194	Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. <i>Gastroenterology</i> , 2016, 151, 902-909.	1.3	52
195	IQGAP2 is a novel interferon-alpha antiviral effector gene acting non-conventionally through the NF- κ B pathway. <i>Journal of Hepatology</i> , 2016, 65, 972-979.	3.7	16
196	Exposure to human immunodeficiency virus/hepatitis C virus in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types. <i>Hepatology</i> , 2016, 64, 1951-1968.	7.3	36
197	Treatment of Hepatitis B: A Concise Review. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e190.	2.5	25
198	Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2016, 24, 848-862.	16.2	279

#	ARTICLE	IF	CITATIONS
199	The epigenetic landscape of T cell exhaustion. <i>Science</i> , 2016, 354, 1165-1169.	12.6	694
200	Long noncoding RNAs expressed in human hepatic stellate cells form networks with extracellular matrix proteins. <i>Genome Medicine</i> , 2016, 8, 31.	8.2	59
201	New perspectives for preventing hepatitis C virus liver graft infection. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 735-745.	9.1	41
202	Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. <i>Hepatology</i> , 2016, 64, 1442-1450.	7.3	126
203	Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. <i>Liver International</i> , 2016, 36, 807-816.	3.9	270
204	Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 381-391.	1.9	45
205	A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e153.	2.5	26
206	HCV compartmentalization in HCC: driver, passenger or both?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 254-256.	17.8	5
207	Reply to antiviral therapy and hepatocellular carcinogenesis. <i>Cancer</i> , 2016, 122, 158-158.	4.1	2
208	Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2108-2117.	2.3	67
209	Using an Electronic Medical Records Database to Identify Non-Traditional Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 671-676.	0.4	22
210	Association Between Plasma Level of Galectin-9 and Survival of Patients With Drug-Induced Acute Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 606-612.e3.	4.4	15
211	A role for retromer in hepatitis C virus replication. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 869-881.	5.4	28
212	Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2016, 11, e0158431.	2.5	79
213	Anti-hepatocellular carcinoma properties of the anti-alcoholism drug disulfiram discovered to enzymatically inhibit the AMPK-related kinase SNARK <i>in vitro</i> . <i>Oncotarget</i> , 2016, 7, 74987-74999.	1.8	7
214	T2 relaxation time is related to liver fibrosis severity. <i>Quantitative Imaging in Medicine and Surgery</i> , 2016, 6, 103-114.	2.0	54
215	Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C. <i>World Journal of Gastroenterology</i> , 2016, 22, 9954.	3.3	6
216	Reply to: "Coagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitis". <i>Journal of Hepatology</i> , 2015, 63, 279.	3.7	1

#	ARTICLE	IF	CITATIONS
217	A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions. <i>Scientific Reports</i> , 2015, 5, 18277.	3.3	58
218	Tackling the hepatitis C cost problem: A test case for tomorrow's cures. <i>Hepatology</i> , 2015, 62, 1334-1336.	7.3	8
219	Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES. <i>BMC Infectious Diseases</i> , 2015, 15, 510.	2.9	22
220	Diabetes and prediabetes in patients with hepatitis B residing in North America. <i>Hepatology</i> , 2015, 62, 1364-1374.	7.3	29
221	Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. <i>Cancer</i> , 2015, 121, 2874-2882.	4.1	63
222	The new hepatitis C virus bottleneck: Can delaying therapy be justified?. <i>Hepatology</i> , 2015, 62, 666-667.	7.3	8
223	Short and Long-Term Effects of Telaprevir on Kidney Function in Patients with Hepatitis C Virus Infection: A Retrospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0124139.	2.5	6
224	Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. <i>International Journal of Nephrology</i> , 2015, 2015, 1-9.	1.3	66
225	Comprehensive serological profiling of human populations using a synthetic human virome. <i>Science</i> , 2015, 348, aaa0698.	12.6	364
226	EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway. <i>Journal of Virology</i> , 2015, 89, 6608-6618.	3.4	37
227	Reply to direct-acting antiviral drugs and hepatitis C virus: A therapeutic revolution?. <i>Cancer</i> , 2015, 121, 4269-4270.	4.1	0
228	Hepatitis C virus NS5A drives a PI3K/Akt feedback loop to support cell survival. <i>Liver International</i> , 2015, 35, 1682-1691.	3.9	42
229	Reduced Albumin Dosing During Large-Volume Paracentesis Is Not Associated with Adverse Clinical Outcomes. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2190-2195.	2.3	10
230	Enhancing Our Understanding of Current Therapies for Hepatitis C Virus (HCV). <i>Current HIV/AIDS Reports</i> , 2015, 12, 68-78.	3.1	29
231	The Polymerase Chain Reaction: Essential for the Development of Curative Therapy for Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2232-2235.	2.3	1
232	Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2523-2528.	2.3	46
233	B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2236-2243.	0.9	120
234	Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study. <i>Liver International</i> , 2015, 35, 370-380.	3.9	59

#	ARTICLE	IF	CITATIONS
235	Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. <i>Hepatology</i> , 2015, 62, 365-374.	7.3	91
236	Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 222-232.e2.	4.5	209
237	Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e114.	2.5	42
238	Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. <i>Nature Medicine</i> , 2015, 21, 1290-1297.	30.7	214
239	Host-targeting agents for treatment of hepatitis B virus infection. <i>Current Opinion in Virology</i> , 2015, 14, 41-46.	5.4	33
240	Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act. <i>The Lancet Global Health</i> , 2015, 3, e358-e359.	6.3	39
241	Amyloidosis of the liver on shear wave elastography: case report and review of literature. <i>Abdominal Imaging</i> , 2015, 40, 3078-3083.	2.0	17
242	Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. <i>Infectious Diseases</i> , 2015, 47, 924-929.	2.8	63
243	The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing. <i>Journal of Hepatology</i> , 2015, 62, 1024-1032.	3.7	24
244	Hepatitis C Virus-Associated Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2015, 10, 345-370.	22.4	79
245	Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study. <i>Gastroenterology</i> , 2015, 148, 100-107.e1.	1.3	307
246	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. <i>Gut</i> , 2015, 64, 1296-1302.	12.1	70
247	Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. <i>Journal of Hepatology</i> , 2015, 62, 18-23.	3.7	96
248	TRAIL Enhances Apoptosis of Human Hepatocellular Carcinoma Cells Sensitized by Hepatitis C Virus Infection: Therapeutic Implications. <i>PLoS ONE</i> , 2014, 9, e98171.	2.5	12
249	The Effect of Hepatitis C Virologic Clearance on Cardiovascular Disease Biomarkers in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu104.	0.9	28
250	Curing Chronic Hepatitis C – The Arc of a Medical Triumph. <i>New England Journal of Medicine</i> , 2014, 370, 1576-1578.	27.0	203
251	Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. <i>Current Pathobiology Reports</i> , 2014, 2, 245-256.	3.4	30
252	Optimal Antiviral Prophylaxis Against Hepatitis B Reactivation in Patients Receiving Rituximab-Based Chemotherapy for Lymphoma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2505.	7.4	9

#	ARTICLE	IF	CITATIONS
253	Widespread Morbilliform Eruption Associated With Telaprevir. <i>JAMA Dermatology</i> , 2014, 150, 756.	4.1	7
254	Hepatitis C treatment: an incipient therapeutic revolution. <i>Trends in Molecular Medicine</i> , 2014, 20, 315-321.	6.7	42
255	Kinetic differences in the induction of interferon stimulated genes by interferon- λ and interleukin 28B are altered by infection with hepatitis C virus. <i>Hepatology</i> , 2014, 59, 1250-1261.	7.3	102
256	Direct-Acting Antiviral Agents and the Path to Interferon Independence. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 728-737.	4.4	34
257	Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, S79-S90.	3.7	181
258	HCV and HIV co-infection: mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 362-371.	17.8	148
259	Poor Adherence to AASLD Guidelines for Chronic Hepatitis B Management and Treatment in a Large Academic Medical Center. <i>American Journal of Gastroenterology</i> , 2014, 109, 867-875.	0.4	57
260	Antiviral treatment of hepatitis C. <i>BMJ, The</i> , 2014, 349, g3308-g3308.	6.0	175
261	Advanced Disease, Diuretic Use, and Marital Status Predict Hospital Admissions in an Ambulatory Cirrhosis Cohort. <i>Digestive Diseases and Sciences</i> , 2014, 59, 174-182.	2.3	18
262	Entry inhibitors and future treatment of hepatitis C. <i>Antiviral Research</i> , 2014, 104, 136-142.	4.1	20
263	Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e114747.	2.5	11
264	Dual Activators of Protein Kinase R (PKR) and Protein Kinase R-Like Kinase (PERK) Identify Common and Divergent Catalytic Targets. <i>ChemBioChem</i> , 2013, 14, 1255-1262.	2.6	20
265	The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF- β signaling. <i>Journal of Hepatology</i> , 2013, 59, 942-948.	3.7	26
266	Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1024-1030.	1.3	195
267	Pharmacological Inhibition of a MicroRNA Family in Nonhuman Primates by a Seed-Targeting 8-Mer AntimiR. <i>Science Translational Medicine</i> , 2013, 5, 212ra162.	12.4	109
268	After the Cure: Management of HCV After Achievement of SVR. <i>Current HIV/AIDS Reports</i> , 2013, 10, 428-435.	3.1	10
269	Reply. <i>Gastroenterology</i> , 2013, 144, e26.	1.3	0
270	SOCS1 abrogates IFN α 's antiviral effect on hepatitis C virus replication. <i>Antiviral Research</i> , 2013, 97, 101-107.	4.1	21

#	ARTICLE	IF	CITATIONS
271	A Genetic Screen Identifies Interferon- λ Effector Genes Required to Suppress Hepatitis C Virus Replication. <i>Gastroenterology</i> , 2013, 144, 1438-1449.e9.	1.3	37
272	One more piece in the interleukin 28B gene puzzle? The case of hepatitis B. <i>Hepatology</i> , 2013, 57, 870-872.	7.3	9
273	HCV and Host Lipids: An Intimate Connection. <i>Seminars in Liver Disease</i> , 2013, 33, 358-368.	3.6	48
274	Circulating Mitochondrial DNA in Patients in the ICU as a Marker of Mortality: Derivation and Validation. <i>PLoS Medicine</i> , 2013, 10, e1001577.	8.4	354
275	In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. <i>American Journal of Clinical Nutrition</i> , 2013, 98, 423-429.	4.7	6
276	Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts. <i>Annals of Internal Medicine</i> , 2013, 158, 235.	3.9	187
277	The Absence of Obstructive Sleep Apnea May Protect against Non-Alcoholic Fatty Liver in Patients Undergoing Bariatric Surgery. <i>PLoS ONE</i> , 2013, 8, e62504.	2.5	14
278	Impact of Peginterferon Alpha and Ribavirin Treatment on Lipid Profiles and Insulin Resistance in Hepatitis C Virus/HIV-Coinfected Persons: The AIDS Clinical Trials Group A5178 Study. <i>Clinical Infectious Diseases</i> , 2012, 55, 631-638.	5.8	14
279	Management of hepatitis B reactivation in patients receiving cancer chemotherapy. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 359-370.	3.2	20
280	The Dose-Response Relationship of Peginterferon Alfa-2a and Ribavirin in the Treatment of Patients Coinfected with HIV-HCV. <i>HIV Clinical Trials</i> , 2012, 13, 33-45.	2.0	9
281	Extended Therapy With Pegylated Interferon and Weight-Based Ribavirin for HCV-HIV Coinfected Patients. <i>HIV Clinical Trials</i> , 2012, 13, 70-82.	2.0	11
282	Anti-Hepatitis C Virus Drugs in Development. <i>Gastroenterology</i> , 2012, 142, 1340-1350.e1.	1.3	83
283	Lipid Metabolite Profiling Identifies Desmosterol Metabolism as a New Antiviral Target for Hepatitis C Virus. <i>Journal of the American Chemical Society</i> , 2012, 134, 6896-6899.	13.7	41
284	A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. <i>Journal of Hepatology</i> , 2012, 56, 326-333.	3.7	60
285	Inhibition of HCV by the serpin antithrombin III. <i>Virology Journal</i> , 2012, 9, 226.	3.4	14
286	Development of an Accurate Index for Predicting Outcomes of Patients With Acute Liver Failure. <i>Gastroenterology</i> , 2012, 143, 1237-1243.	1.3	125
287	Future Classes of Hepatitis C Virus Therapeutic Agents. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 949-966.	5.1	2
288	ARF1 and GBF1 Generate a PI4P-Enriched Environment Supportive of Hepatitis C Virus Replication. <i>PLoS ONE</i> , 2012, 7, e32135.	2.5	57

#	ARTICLE	IF	CITATIONS
289	Hepatitis C Virus NS5A Disrupts STAT1 Phosphorylation and Suppresses Type I Interferon Signaling. <i>Journal of Virology</i> , 2012, 86, 8581-8591.	3.4	73
290	Novel Therapies for Hepatitis C: Insights from the Structure of the Virus. <i>Annual Review of Medicine</i> , 2012, 63, 373-387.	12.2	36
291	Short and Long-Term Outcomes in Patients with Acute Liver Failure Due to Ischemic Hepatitis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 777-785.	2.3	52
292	Serum Vitamin D Levels Are Not Predictive of the Progression of Chronic Liver Disease in Hepatitis C Patients with Advanced Fibrosis. <i>PLoS ONE</i> , 2012, 7, e27144.	2.5	38
293	Hepatitis C Virus Treatment in HIV. , 2012, , 133-139.		0
294	Spontaneous Control of HCV Is Associated With Expression of HLA-B*57 and Preservation of Targeted Epitopes. <i>Gastroenterology</i> , 2011, 140, 686-696.e1.	1.3	130
295	A Functional Polymorphism in the Epidermal Growth Factor Gene Is Associated With Risk for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 141, 141-149.	1.3	133
296	HIV and HCV Cooperatively Promote Hepatic Fibrogenesis via Induction of Reactive Oxygen Species and NF κ B. <i>Journal of Biological Chemistry</i> , 2011, 286, 2665-2674.	3.4	99
297	HIV infection increases HCV-induced hepatocyte apoptosis. <i>Journal of Hepatology</i> , 2011, 54, 612-620.	3.7	50
298	IL28B inhibits hepatitis C virus replication through the JAK κ STAT pathway. <i>Journal of Hepatology</i> , 2011, 55, 289-298.	3.7	120
299	New protease inhibitors for HCV κ Help is on the way. <i>Journal of Hepatology</i> , 2011, 54, 1087-1089.	3.7	13
300	Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. <i>Journal of Hepatology</i> , 2011, 55, 963-971.	3.7	121
301	IL28B Alleles Exert an Additive Dose Effect When Applied to HCV-HIV Coinfected Persons Undergoing Peginterferon and Ribavirin Therapy. <i>PLoS ONE</i> , 2011, 6, e25753.	2.5	19
302	Chronic Hepatitis C. <i>Gut and Liver</i> , 2011, 5, 117-132.	2.9	29
303	The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort. <i>Digestive Diseases and Sciences</i> , 2011, 56, 564-568.	2.3	58
304	Hepatocellular Carcinoma Screening Rates Vary by Etiology of Cirrhosis and Involvement of Gastrointestinal Sub-specialists. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3316-3322.	2.3	29
305	The Impact of Human Gene Polymorphisms on HCV Infection and Disease Outcome. <i>Seminars in Liver Disease</i> , 2011, 31, 375-386.	3.6	19
306	Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 597-605.	2.1	26

#	ARTICLE	IF	CITATIONS
307	HIV and HCV Coinfection: Where Are We in 2010?. <i>Current Hepatitis Reports</i> , 2010, 9, 155-160.	0.3	2
308	A Randomized Controlled Trial of Double Versus Triple Therapy with Amantadine for Genotype 1 Chronic Hepatitis C in Latino Patients. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2629-2635.	2.3	7
309	Reply:. <i>Hepatology</i> , 2010, 51, 343-344.	7.3	0
310	Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 1906-1914.	7.3	10
311	When Treating Cancer, Please Don't Forget Hepatitis B. <i>Oncologist</i> , 2010, 15, 826-829.	3.7	4
312	Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop. <i>American Journal of Gastroenterology</i> , 2010, 105, 989-1004.	0.4	30
313	Hepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIVâ€Coinfected Subjects Treated with Interferonâ€Based Regimens. <i>Journal of Infectious Diseases</i> , 2010, 201, 100127142343070-000.	4.0	17
314	Reduction of Insulin Resistance With Effective Clearance of Hepatitis C Infection: Results From the HALT-C Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 458-462.	4.4	80
315	Reaping the Early Harvest of the Genomics Revolution. <i>Gastroenterology</i> , 2010, 138, 1653-1654.	1.3	2
316	Suppressor of Cytokine Signaling 3 Suppresses Hepatitis C Virus Replication in an mTOR-Dependent Manner. <i>Journal of Virology</i> , 2010, 84, 6060-6069.	3.4	41
317	Hepatitis C Virus Regulates Transforming Growth Factor Î²1 Production Through the Generation of Reactive Oxygen Species in a Nuclear Factor Î²Bâ€Dependent Manner. <i>Gastroenterology</i> , 2010, 138, 2509-2518.e1.	1.3	177
318	Rate of Sustained Virologic Response in Relation to Baseline Hepatitis C Virus (HCV) RNA Level and Rapid Virologic Clearance in Persons with Acute HCV Infection. <i>Journal of Infectious Diseases</i> , 2009, 200, 877-881.	4.0	21
319	Improving the Diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria. <i>Clinical Infectious Diseases</i> , 2009, 49, 1051-1060.	5.8	90
320	Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. <i>Hepatology</i> , 2009, 49, 1828-1837.	7.3	51
321	Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. <i>Hepatology</i> , 2009, 49, 1847-1858.	7.3	75
322	Monitoring during and after antiviral therapy for hepatitis B. <i>Hepatology</i> , 2009, 49, S166-S173.	7.3	51
323	Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up. <i>Hepatology</i> , 2009, 50, 1030-1037.	7.3	169
324	The effect of angiotensinâ€blocking agents on liver fibrosis in patients with hepatitis C. <i>Liver International</i> , 2009, 29, 748-753.	3.9	75

#	ARTICLE	IF	CITATIONS
325	Treatment failure in hepatitis C: Mechanisms of non-response. <i>Journal of Hepatology</i> , 2009, 50, 412-420.	3.7	50
326	Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. <i>Journal of Hepatology</i> , 2009, 50, 705-711.	3.7	57
327	Coinfection With HIV-1 and HCV—A One-Two Punch. <i>Gastroenterology</i> , 2009, 137, 795-814.	1.3	152
328	Prospective study of liver transplant recipients with HCV infection: Evidence for a causal relationship between HCV and insulin resistance. <i>Liver Transplantation</i> , 2008, 14, 193-201.	2.4	56
329	Extrahepatic hepatitis C virus after transplantation: Diabetes and renal dysfunction. <i>Liver Transplantation</i> , 2008, 14, S51-S57.	2.4	12
330	Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. <i>Hepatology</i> , 2008, 47, 1437-1445.	7.3	226
331	Development of novel agents for the treatment of hepatitis C virus. <i>Hepatology</i> , 2008, 47, 1426-1426.	7.3	0
332	Reply:. <i>Hepatology</i> , 2008, 47, 2142-2143.	7.3	0
333	Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. <i>Hepatology</i> , 2008, 48, 1769-1778.	7.3	326
334	Avoiding therapeutic pitfalls: The rational use of specifically targeted agents against hepatitis C infection. <i>Hepatology</i> , 2008, 48, 1700-1712.	7.3	28
335	HIV Increases HCV Replication in a TGF- β 1-Dependent Manner. <i>Gastroenterology</i> , 2008, 134, 803-811.	1.3	132
336	De Novo Autoimmune Hepatitis during Immune Reconstitution in an HIV-Infected Patient Receiving Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 46, e12-e14.	5.8	48
337	Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 53-60.	7.4	183
338	The Role of Early Viral Decline in the Treatment of Hepatitis C in HIV-1-Coinfected Persons. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 371-373.	2.1	1
339	Hematologic Toxicity Associated with Interferon-Based Hepatitis C Therapy in HIV Type 1-Coinfected Subjects. <i>Clinical Infectious Diseases</i> , 2007, 44, 1375-1383.	5.8	15
340	Compartmentalization of Hepatitis C Virus (HCV) during HCV/HIV Coinfection. <i>Journal of Infectious Diseases</i> , 2007, 195, 1765-1773.	4.0	47
341	Viral Factors Associated with Cytokine Expression During HCV/HIV Co-Infection. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 263-270.	1.2	9
342	Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 245-254.	4.4	46

#	ARTICLE	IF	CITATIONS
343	Serum Apoptosis Markers in Acute Liver Failure: A Pilot Study. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1477-1483.	4.4	63
344	A Cell-Based, High-Throughput Screen for Small Molecule Regulators of Hepatitis C Virus Replication. <i>Gastroenterology</i> , 2007, 132, 311-320.	1.3	86
345	Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial. <i>Hepatology</i> , 2007, 45, 895-898.	7.3	105
346	Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. <i>Cancer</i> , 2007, 109, 2490-2496.	4.1	170
347	Effects of HCV Treatment on Cytokine Expression During HCV/HIV Coinfection. <i>Journal of Interferon and Cytokine Research</i> , 2006, 26, 834-838.	1.2	13
348	Hepatitis C Virus in the HIV-Infected Patient. <i>Clinics in Liver Disease</i> , 2006, 10, 303-320.	2.1	21
349	Influence of High Body Mass Index on Outcome in Acute Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1544-1549.	4.4	57
350	Roles of Iron and HFE Mutations on Severity and Response to Therapy During Retreatment of Advanced Chronic Hepatitis C. <i>Gastroenterology</i> , 2006, 131, 1440-1451.	1.3	83
351	Case 15-2006. <i>New England Journal of Medicine</i> , 2006, 354, 2166-2175.	27.0	31
352	Assessment of efficacy of treatment in HCV: Infection and disease. <i>Journal of Hepatology</i> , 2006, 44, S56-S59.	3.7	6
353	Treatment of Type II Cryoglobulinemia Associated With Hepatitis C With Rituximab. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 450.	2.2	13
354	Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. <i>Aids</i> , 2006, 20, 345-351.	2.2	14
355	Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection. <i>Journal of Medical Virology</i> , 2006, 78, 202-207.	5.0	35
356	GB Virus C (GBV β C) Infection in Hepatitis C Virus (HCV)/HIV β Coinfected Patients Receiving HCV Treatment: Importance of the GBV β C Genotype. <i>Journal of Infectious Diseases</i> , 2006, 194, 410-419.	4.0	56
357	Case 33-2006. <i>New England Journal of Medicine</i> , 2006, 355, 1812-1819.	27.0	15
358	Hepatitis C Virus Core Protein Blocks Interferon Signaling by Interaction with the STAT1 SH2 Domain. <i>Journal of Virology</i> , 2006, 80, 9226-9235.	3.4	167
359	Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. <i>Aids</i> , 2005, 19, 767-773.	2.2	30
360	The magnitude and breadth of hepatitis C virus β C-specific CD8 β T cells depend on absolute CD4 β T-cell count in individuals coinfecting with HIV-1. <i>Blood</i> , 2005, 105, 1170-1178.	1.4	110

#	ARTICLE	IF	CITATIONS
361	Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. <i>Hepatology</i> , 2005, 41, 660-667.	7.3	80
362	Cytokine polymorphisms and hepatocellular carcinoma. <i>Cancer</i> , 2005, 103, 654-656.	4.1	5
363	Gc-globulin and prognosis in acute liver failure. <i>Liver Transplantation</i> , 2005, 11, 1223-1227.	2.4	57
364	Update on hepatitis B and C coinfection in HIV. <i>Current Infectious Disease Reports</i> , 2005, 7, 299-308.	3.0	4
365	Steroid-Responsive (Autoimmune?) Sclerosing Cholangitis. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1839-1843.	2.3	10
366	Acute Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2005, 41, S14-S17.	5.8	38
367	Detection of Hepatitis C Virus (HCV) in Serum and Peripheral Blood Mononuclear Cells from HCV-Monoinfected and HIV/HCV-Coinfected Persons. <i>Journal of Infectious Diseases</i> , 2005, 192, 258-265.	4.0	78
368	Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in "difficult-to-treat" groups and implications for novel treatment approaches. <i>Journal of Hepatology</i> , 2005, 43, 748-750.	3.7	3
369	Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. <i>Gastroenterology</i> , 2005, 128, 313-327.	1.3	97
370	Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. <i>Gastroenterology</i> , 2005, 128, 1034-1041.	1.3	141
371	Hemojuvelin Acts as a Bone Morphogenetic Protein Co-Receptor To Regulate Heparin Expression.. <i>Blood</i> , 2005, 106, 511-511.	1.4	5
372	Peginterferon α -2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections. <i>ACP Journal Club</i> , 2005, 142, A12.	0.1	2
373	HIV and hepatitis C virus coinfection update. <i>Current Hepatitis Reports</i> , 2004, 3, 83-90.	0.3	1
374	Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. <i>Clinical Transplantation</i> , 2004, 18, 166-173.	1.6	99
375	Liver transplantation outcomes for early-stage hepatocellular carcinoma: Results of a multicenter study. <i>Liver Transplantation</i> , 2004, 10, 1343-1354.	2.4	126
376	Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons. <i>New England Journal of Medicine</i> , 2004, 351, 451-459.	27.0	856
377	New antiviral therapies for hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , 2004, 2, 235-243.	4.4	0
378	Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. <i>Transplantation</i> , 2004, 77, 703-710.	1.0	112

#	ARTICLE	IF	CITATIONS
379	Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. <i>Gastroenterology</i> , 2003, 124, 1946-1949.	1.3	47
380	Human Immunodeficiency Virus Type 1-Hepatitis C Virus Coinfection: Intraindividual Comparison of Cellular Immune Responses against Two Persistent Viruses. <i>Journal of Virology</i> , 2002, 76, 2817-2826.	3.4	101
381	Rapidly progressive fibrosing cholestatic hepatitis-hepatitis C virus in HIV coinfection. <i>American Journal of Gastroenterology</i> , 2002, 97, 478-483.	0.4	62
382	Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials Group. <i>Clinical Infectious Diseases</i> , 2002, 34, 831-837.	5.8	678
383	Viral RNA Mutations Are Region Specific and Increased by Ribavirin in a Full-Length Hepatitis C Virus Replication System. <i>Journal of Virology</i> , 2002, 76, 8505-8517.	3.4	187
384	Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. <i>Aids</i> , 2002, 16, 1915-1923.	2.2	146
385	New developments in the management of hepatitis B virus/HIV coinfection. <i>MedGenMed: Medscape General Medicine</i> , 2002, 4, 20.	0.2	0
386	POSTTRANSPLANT DIABETES MELLITUS IN LIVER TRANSPLANT RECIPIENTS: RISK FACTORS, TEMPORAL RELATIONSHIP WITH HEPATITIS C VIRUS ALLOGRAFT HEPATITIS, AND IMPACT ON MORTALITY1. <i>Transplantation</i> , 2001, 72, 1066-1072.	1.0	257
387	Approach to the Management of Allograft Recipients Following the Detection of Hepatitis B Virus in the Prospective Organ Donor. <i>American Journal of Transplantation</i> , 2001, 1, 185-191.	4.7	86
388	Prevalence of hepatitis C virus-associated mixed cryoglobulinemia after liver transplantation. <i>Liver Transplantation</i> , 2000, 6, 185-190.	2.4	26
389	Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus. <i>Journal of Experimental Medicine</i> , 2000, 191, 1499-1512.	8.5	1,165
390	Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. <i>Journal of Medical Virology</i> , 1999, 58, 353-358.	5.0	70
391	Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. <i>Journal of Medical Virology</i> , 1999, 58, 353-358.	5.0	1
392	Renal Thrombotic Microangiopathy Associated with Anticardiolipin Antibodies in Hepatitis C-Positive Renal Allograft Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 146-153.	6.1	167
393	NEPHROTIC SYNDROME AFTER LIVER TRANSPLANTATION IN A PATIENT WITH HEPATITIS C VIRUS-ASSOCIATED GLOMERULONEPHRITIS1. <i>Transplantation</i> , 1997, 64, 1073-1076.	1.0	32
394	Just say "no" to viral hepatitis?. <i>Hepatology</i> , 1994, 19, 790-792.	7.3	3
395	A Role for Hepatitis C Virus Infection in Type II Cryoglobulinemia. <i>New England Journal of Medicine</i> , 1992, 327, 1490-1495.	27.0	1,282
396	LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients. <i>Biomarkers in Medicine</i> , 0, , .	1.4	1